242 related articles for article (PubMed ID: 21327941)
1. Adult grade II diffuse astrocytomas are genetically distinct from and more aggressive than their paediatric counterparts.
Jones DT; Mulholland SA; Pearson DM; Malley DS; Openshaw SW; Lambert SR; Liu L; Bäcklund LM; Ichimura K; Collins VP
Acta Neuropathol; 2011 Jun; 121(6):753-61. PubMed ID: 21327941
[TBL] [Abstract][Full Text] [Related]
2. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival.
Thon N; Eigenbrod S; Kreth S; Lutz J; Tonn JC; Kretzschmar H; Peraud A; Kreth FW
Cancer; 2012 Jan; 118(2):452-60. PubMed ID: 21717448
[TBL] [Abstract][Full Text] [Related]
3. WT1 expression increases with malignancy and indicates unfavourable outcome in astrocytoma.
Rauscher J; Beschorner R; Gierke M; Bisdas S; Braun C; Ebner FH; Schittenhelm J
J Clin Pathol; 2014 Jul; 67(7):556-61. PubMed ID: 24607494
[TBL] [Abstract][Full Text] [Related]
4. Primary Astrocytic Tumours and Paired Recurrences have Similar Biological Features in IDH1, TP53 and TERTp Mutation and MGMT, ATRX Loss.
Li X; Wei J; Liu Y; Li P; Fan L; Wang Y; Li M; Zhao D; Yu Z; Ye J; Guo Y; Yan Q; Guo S; Wang Z
Sci Rep; 2017 Oct; 7(1):13038. PubMed ID: 29026176
[TBL] [Abstract][Full Text] [Related]
5. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme.
Kalkan R; Atli Eİ; Özdemir M; Çiftçi E; Aydin HE; Artan S; Arslantaş A
Gene; 2015 Jan; 554(1):81-6. PubMed ID: 25455102
[TBL] [Abstract][Full Text] [Related]
6. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
[TBL] [Abstract][Full Text] [Related]
7. Association between MGMT promoter hypermethylation and p53 mutation in glioblastoma.
Shamsara J; Sharif S; Afsharnezhad S; Lotfi M; Raziee HR; Ghaffarzadegan K; Moradi A; Rahighi S; Behravan J
Cancer Invest; 2009 Oct; 27(8):825-9. PubMed ID: 19544111
[TBL] [Abstract][Full Text] [Related]
8. Gliomatosis cerebri: no evidence for a separate brain tumor entity.
Herrlinger U; Jones DTW; Glas M; Hattingen E; Gramatzki D; Stuplich M; Felsberg J; Bähr O; Gielen GH; Simon M; Wiewrodt D; Schabet M; Hovestadt V; Capper D; Steinbach JP; von Deimling A; Lichter P; Pfister SM; Weller M; Reifenberger G
Acta Neuropathol; 2016 Feb; 131(2):309-319. PubMed ID: 26493382
[TBL] [Abstract][Full Text] [Related]
9. MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation.
Groenendijk FH; Taal W; Dubbink HJ; Haarloo CR; Kouwenhoven MC; van den Bent MJ; Kros JM; Dinjens WN
J Neurooncol; 2011 Feb; 101(3):405-17. PubMed ID: 20593220
[TBL] [Abstract][Full Text] [Related]
10. O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation is significantly less frequent in ependymal tumours as compared to malignant astrocytic gliomas.
Koos B; Peetz-Dienhart S; Riesmeier B; Frühwald MC; Hasselblatt M
Neuropathol Appl Neurobiol; 2010 Jun; 36(4):356-8. PubMed ID: 20202118
[No Abstract] [Full Text] [Related]
11. ATRX loss in adult supratentorial diffuse astrocytomas correlates with p53 over expression and IDH1 mutation and predicts better outcome in p53 accumulated patients.
Shao LW; Pan Y; Qi XL; Li YX; Ma XL; Yi WN; Zhang J; Zhong YF; Chang Q
Histol Histopathol; 2016 Jan; 31(1):103-14. PubMed ID: 26395639
[TBL] [Abstract][Full Text] [Related]
12. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
Hartmann C; Meyer J; Balss J; Capper D; Mueller W; Christians A; Felsberg J; Wolter M; Mawrin C; Wick W; Weller M; Herold-Mende C; Unterberg A; Jeuken JW; Wesseling P; Reifenberger G; von Deimling A
Acta Neuropathol; 2009 Oct; 118(4):469-74. PubMed ID: 19554337
[TBL] [Abstract][Full Text] [Related]
13. Detection of IDH1 mutations in gliomatosis cerebri, but only in tumors with additional solid component: evidence for molecular subtypes.
Seiz M; Tuettenberg J; Meyer J; Essig M; Schmieder K; Mawrin C; von Deimling A; Hartmann C
Acta Neuropathol; 2010 Aug; 120(2):261-7. PubMed ID: 20514489
[TBL] [Abstract][Full Text] [Related]
14. p53 abnormality and tumor invasion in patients with malignant astrocytoma.
Momota H; Narita Y; Matsushita Y; Miyakita Y; Shibui S
Brain Tumor Pathol; 2010 Oct; 27(2):95-101. PubMed ID: 21046311
[TBL] [Abstract][Full Text] [Related]
15. Association of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation with p53 mutation occurrence in non-small cell lung cancer with different histology, gender, and smoking status.
Wu JY; Wang J; Lai JC; Cheng YW; Yeh KT; Wu TC; Chen CY; Lee H
Ann Surg Oncol; 2008 Nov; 15(11):3272-7. PubMed ID: 18712569
[TBL] [Abstract][Full Text] [Related]
16. MGMT CpG island is invariably methylated in adult astrocytic and oligodendroglial tumors with IDH1 or IDH2 mutations.
Mulholland S; Pearson DM; Hamoudi RA; Malley DS; Smith CM; Weaver JM; Jones DT; Kocialkowski S; Bäcklund LM; Collins VP; Ichimura K
Int J Cancer; 2012 Sep; 131(5):1104-13. PubMed ID: 22020830
[TBL] [Abstract][Full Text] [Related]
17. Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma.
Korshunov A; Meyer J; Capper D; Christians A; Remke M; Witt H; Pfister S; von Deimling A; Hartmann C
Acta Neuropathol; 2009 Sep; 118(3):401-5. PubMed ID: 19543740
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytoma: a long-term analysis.
Ständer M; Peraud A; Leroch B; Kreth FW
Cancer; 2004 Sep; 101(5):1028-35. PubMed ID: 15329912
[TBL] [Abstract][Full Text] [Related]
19. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas.
Okamoto Y; Di Patre PL; Burkhard C; Horstmann S; Jourde B; Fahey M; Schüler D; Probst-Hensch NM; Yasargil MG; Yonekawa Y; Lütolf UM; Kleihues P; Ohgaki H
Acta Neuropathol; 2004 Jul; 108(1):49-56. PubMed ID: 15118874
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients.
Felsberg J; Rapp M; Loeser S; Fimmers R; Stummer W; Goeppert M; Steiger HJ; Friedensdorf B; Reifenberger G; Sabel MC
Clin Cancer Res; 2009 Nov; 15(21):6683-93. PubMed ID: 19861461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
